Leukocyte Immunoglobulin-like Receptors Regulate The Function Of The Major Cells Involved In Allergic Inflammation.
Funder
National Health and Medical Research Council
Funding Amount
$254,250.00
Summary
An important aspect of the immune system is its ability to maintain a delicate equilibrium between the extremes of reactivity and quiescence. A break in this equilibrium can lead to unchecked activation of immune cells or inability of these cells to mount an effective defence. Potential outcomes of the unchecked activation of cells are autoimmune diseases such as rheumatoid arthritis or allergic diseases such as asthma. A new family of cell surface proteins termed leukocyte immunoglobulin-like r ....An important aspect of the immune system is its ability to maintain a delicate equilibrium between the extremes of reactivity and quiescence. A break in this equilibrium can lead to unchecked activation of immune cells or inability of these cells to mount an effective defence. Potential outcomes of the unchecked activation of cells are autoimmune diseases such as rheumatoid arthritis or allergic diseases such as asthma. A new family of cell surface proteins termed leukocyte immunoglobulin-like receptors (LIRs) has been shown to regulate immune cells by either increasing or decreasing their activity. In this project we will study the role of LIRs in regulating the activity of the major cells involved in allergy and asthma. This study would provide important insights to mechanism(s) of regulation of immune cell activation during protective immune responses such as the fight against infections and cancers and during pathological inflammations such as asthma and rheumatoid arthritis. Understanding the role of the LIRs in the regulation of immune cell activation might lead to new therapeutic strategies aimed at restoring the balance between the inhibitory and activating LIRs.Read moreRead less
Pattern Recognition Receptors In Inflammation And Infection
Funder
National Health and Medical Research Council
Funding Amount
$622,655.00
Summary
Innate immunity provides our first line of defence against infections, but pathogens can overcome this system. Understanding how microbes disable innate immunity can teach us how to prevent and/or treat infectious diseases. Innate immunity acts by initiating inflammation. Many important acute and chronic diseases develop when this process is dysregulated. Blocking innate immunity thus has potential to treat many diseases. This project aims to understand innate immunity in these contexts.
Simplified Process Methods For Mass Vaccine Manufacture
Funder
National Health and Medical Research Council
Funding Amount
$158,393.00
Summary
The ideal way to protect against pandemic bird flu is to vaccinate all Australians as soon as possible after a dangerous strain starts to spread. Current manufacturing technology, which begins by making an infectious virus in chicken eggs, is unable to quickly deliver a mass vaccine to the entire Australian population. The existing process is slow, meaning that it will take several months before enough vaccine is available even to protect personnel working in essential services. The product from ....The ideal way to protect against pandemic bird flu is to vaccinate all Australians as soon as possible after a dangerous strain starts to spread. Current manufacturing technology, which begins by making an infectious virus in chicken eggs, is unable to quickly deliver a mass vaccine to the entire Australian population. The existing process is slow, meaning that it will take several months before enough vaccine is available even to protect personnel working in essential services. The product from chicken eggs is rendered safe after manufacture by breaking the virus structure. This make then break strategy reduces vaccine effectiveness meaning that even fewer individuals can be effectively protected per vaccine batch. Recent scientific progress has demonstrated that it is possible to make a non-infectious empty virus shell (a so-called virus-like particle) inside cells. This new product is able to provide full protection against a lethal influenza challenge, when administered nasally. However, these particles are very difficult to purify from contaminants that are packaged into the particles during manufacture in cells. These contaminants can cause an adverse reaction when the product is given to humans, meaning that although the product is effective it remains difficult to mass produce. A manufacturing problem remains. To overcome this manufacturing problem we will seek to assemble vaccine particles in vitro, building the particle from purified protein. Existing technology for manufacturing pure pharmaceutical protein is well-established and safe, and allows mass manufacture of contaminant-free product. This new make don't break manufacturing strategy is similar to that chosen by Merck to deliver a safe and effective vaccine, for cervical cancer, to mass market. Our key aim is to adapt this efficient manufacturing strategy to the manufacture of influenza vaccine. If successful, we will be able to immunize the Australian population using existing national biomanufacturing capability, within weeks of new strain identification, and without the requirement for high-level containment during manufacture.Read moreRead less